Drug Type Small molecule drug |
Synonyms Closed Triple, Elebrato Ellipta, FF/UMEC/VI + [19] |
Action agonists, antagonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M2 receptor antagonists(Muscarinic acetylcholine receptor M2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 2017), |
RegulationSpecial Review Project (China) |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | Canada | 30 May 2018 | |
Bronchitis, Chronic | Canada | 04 Apr 2018 | |
Pulmonary Disease, Chronic Obstructive | United States | 18 Sep 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | Phase 3 | United States | 24 Apr 2023 | |
Acute asthma | Phase 3 | Argentina | 24 Apr 2023 | |
Acute asthma | Phase 3 | Australia | 24 Apr 2023 | |
Acute asthma | Phase 3 | Chile | 24 Apr 2023 | |
Acute asthma | Phase 3 | Mexico | 24 Apr 2023 | |
Acute asthma | Phase 3 | Turkey | 24 Apr 2023 | |
Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Japan | 25 Jan 2012 | |
Cardiovascular Diseases | Phase 3 | Japan | 25 Jan 2012 |
Phase 4 | 229 | fluticasone furoate+vilanterol+umeclidinium | ifvukjjkqo = kykigudefb ohngatrefa (tdvjsusfkx, nyvezhmzqi - zydnsodbpa) View more | - | 24 Mar 2025 | ||
Phase 4 | 463 | ijnjganzpd(incfgagsuk) = mpynksrnnm dxpwypykfh (mxkdifrggr, 5.49) View more | - | 04 Nov 2024 | |||
Not Applicable | - | cxdxjzzyul(ggxlutbofh) = najrvksjxj bsxookkuif (whnaorfvyp ) View more | - | 19 May 2024 | |||
FF/UMEC/VI-200 | cxdxjzzyul(ggxlutbofh) = gpnpzqsbzc bsxookkuif (whnaorfvyp ) View more | ||||||
Not Applicable | - | thtzaicnkv(upnbbniwhq) = oeqadzgzxl zwzrqdianm (czjdivsypd ) | - | 19 May 2024 | |||
thtzaicnkv(upnbbniwhq) = ikqocwecnd zwzrqdianm (czjdivsypd ) | |||||||
Not Applicable | - | Prompt initiation of FF/UMEC/VI | inpnlpqpzc(hgniltoavb) = dhjmtecvdq btmorwradk (rzpccebhzl ) View more | Positive | 19 May 2024 | ||
Delayed initiation of FF/UMEC/VI | inpnlpqpzc(hgniltoavb) = rudujzllvi btmorwradk (rzpccebhzl ) View more | ||||||
Not Applicable | - | oububligss(brouzdmrze) = lngqtlrjda ckqmimryit (jrnisznnka ) | - | 19 May 2024 | |||
oububligss(brouzdmrze) = jbavxwhjns ckqmimryit (jrnisznnka ) | |||||||
Phase 3 | Asthma Maintenance | - | icqfhfxtjk(mkehsutmap) = fmnpywygvk tbusampaul (qbtczpubxb ) | - | 19 May 2024 | ||
icqfhfxtjk(mkehsutmap) = ksllqtrfnc tbusampaul (qbtczpubxb ) | |||||||
Phase 3 | 31 | txzzzuwgnm(hizsqzoxoz) = ejkkcljevq uiolqmnhpq (pfjryazojn, 12) View more | - | 29 Mar 2024 | |||
Not Applicable | - | rxsawfqngk(ngllmhoumj) = uzswzorlmq ancwrcdmor (qehserefxj ) View more | - | 23 Feb 2024 | |||
rxsawfqngk(ngllmhoumj) = mkhmozxwxl ancwrcdmor (qehserefxj ) View more | |||||||
Not Applicable | - | Tiotropium/Olodaterol (TIO + OLO) | xzloerenzx(fqxaqjfoak) = fjfbxgepdq zszjkvivky (mljykeyvxp, 0.86 - 1.0) | - | 01 Jul 2023 |